New medicines and medical devices reimbursed to patients

The decision of the Reimbursement Commission on Medicinal Products and Medical Devices to include all eight medicines that were on the Reserve List in the list of reimbursable medicines as of February 2024 will help to ensure that patients can receive modern and effective treatment for oncological, lung and heart diseases. The new medicines will be reimbursed with an additional EUR 13.5 million from the budget of the Compulsory Health Insurance Fund (CHIF).

“As the CHIF budget grows each year, more and more medicines that add value to patients’ health and help fight the most serious diseases are being added to the reimbursement system. The eight medicines being transferred from the Reserve List to the list of reimbursable medicines will allow even more effective treatment of oncological, lung and heart diseases,” said Aurimas Pečkauskas, Deputy Minister of Health.

Doctors can now prescribe five new reimbursable medicines to patients:

  • apalutamide - for prostate cancer;
  • osimertinib - for lung cancer;
  • nintedanib - for other chronic fibrotic interstitial lung diseases with a progressive phenotype;
  • atezolizumab - for lung cancer;
  • dapagliflozin - for heart failure.

Three new medicines will be added to the reimbursement system in the near future, once the manufacturers of the medicines have signed agreements with the National Health Insurance Fund on the management of the CHIF expenditure on these medicines:

  • cemiplimab for the treatment of cutaneous squamous cell carcinoma;
  • olaparib for the treatment of epithelial ovarian, fallopian tube, primary peritoneal cancer;
  • pembrolizumab for the treatment of head and neck squamous cell carcinoma.

Since 1 February, the CHIF budget has also reimbursed two medical aids: a personalised surgical instrument for bone oncology patients and a surgical suture coupling and clipping device with titanium suture fixators for the surgical treatment of heart valve lesions. 

Also, pregnant women with gestational diabetes have been reimbursed one insulin needle per syringe per day since 1 February, and the number of diagnostic glucose strips has been increased to 150 strips in the first 3 months after the diagnosis of gestational diabetes, and then up to 50 strips in the following 3 months.

In 2024, the CHIF budget foresees a total of EUR 634 million for medicines, medical devices and rental of medical equipment. 

Ministry of Health Communications Division

The NHIF invites you: